Pharmaceutical companies carry GxP validation obligations that make every software change expensive. Vendors exploit that constraint to charge full support fees for products in Sustaining Engineering. GoVendorFree delivers 50–90% savings with full GxP compatibility — no validation trigger, no migration pressure.
Pharmaceutical organisations run deeply embedded Oracle, SAP, VMware, and IBM estates — and vendors know it. GxP validation obligations, CSV requirements, and regulatory submission dependencies create exactly the switching friction vendors count on when pricing renewals.
SAP's pharma installed base is concentrated on ECC with Quality Management (QM), Batch Management, GTS (Global Trade Services), and SAP EHS (Environmental Health & Safety). These are deeply validated modules. SAP's S/4HANA migration pitch exploits GxP validation costs — the more expensive migration appears, the more leverage SAP has at ECC renewal. TPS removes that leverage entirely. SAP ECC with QM and Batch Management is fully covered under TPS with no modification to validated processes.
Oracle EBS deployments in pharma typically include Oracle Financials, Oracle HRMS, Oracle Manufacturing (OPM — Oracle Process Manufacturing), and Oracle OBIEE for regulatory reporting dashboards. Oracle placed EBS R12.1 in Sustaining Engineering in January 2022. Many pharma EBS estates are on R12.2 approaching maintenance end. TPS covers the full OPM module set — batch process order management, formula management, quality management — with no validated system modifications.
Pharma data centres running VMware virtualisation for validated systems — GMP manufacturing systems, LIMS, ERP production environments, batch execution servers — face the same Broadcom VCF mandate as other industries. For validated VMware environments, the additional complexity is that VCF subscription introduces a change management obligation: the migration from SnS to VCF requires quality review under GMP data integrity guidance. TPS avoids this change event entirely and delivers 80–86% savings vs. VCF.
IBM MQ is the integration backbone for many pharma manufacturing execution environments — connecting SAP to MES, LIMS, DeltaV, and historian systems. IBM DB2 is used for batch data warehousing and regulatory reporting databases at a subset of global pharma organisations. IBM Passport Advantage renewals for MQ and DB2 are annual obligations that rise with price escalation clauses. TPS for IBM MQ and DB2 in pharma environments delivers 60–65% savings with full coverage of MQ integration patterns and DB2 procedural layers used in manufacturing analytics.
SAP uses ECC maintenance end dates to force S/4HANA migration conversations. For pharma, S/4HANA migration means revalidation of the entire ERP system — £5M–£15M in validation overhead alone, before SI fees. TPS removes the migration timeline from SAP's hands.
Oracle places EBS R12.1 and JDE 9.2 in Sustaining Engineering but continues charging 22% annual SnS fees. Pharma organisations pay full support rates for products Oracle no longer actively develops. TPS replaces the support obligation at 62–65% lower cost.
Moving from VMware SnS to VCF subscription introduces a product change event that requires quality system review in GMP environments. TPS avoids this change event entirely — perpetual licence, same software, changed support provider (administrative change only).
SAP's Named User audit strategy in pharma targets indirect access through MES and LIMS integration. Organisations where shop floor systems write data to SAP without named user licences face retroactive licence claims. See our SAP Audit Defence Playbook.
IBM DB2 11.1 entered EOS in September 2023. IBM Extended Support carries a 20% surcharge on Passport Advantage fees. Many pharma organisations are paying PA + Extended Support surcharge for a database IBM no longer actively patches. TPS removes both fees.
SAP's BW/4HANA push is particularly acute in pharma — BW is frequently used for regulatory reporting cubes (batch release, stability data, pharmacovigilance). Migrating BW 7.5 to BW/4HANA triggers revalidation of all regulatory reporting analytics. TPS defers this indefinitely on commercial terms.
The following illustrative model is based on a typical mid-size pharmaceutical group (€5–€15bn revenue, 3–5 manufacturing sites, SAP ECC + Oracle EBS, VMware virtualisation) switching from vendor SnS to TPS across all four vendor areas.
| Vendor / System | Current SnS / PA Cost | TPS Cost | Annual Saving | Saving % |
|---|---|---|---|---|
| SAP ECC with QM, Batch, GTS | £980,000 | £343,000 | £637,000 | 65% |
| SAP BW on HANA (regulatory analytics) | £420,000 | £155,400 | £264,600 | 63% |
| Oracle EBS R12.2 (Finance + OPM) | £560,000 | £201,600 | £358,400 | 64% |
| VMware vSphere + vSAN + NSX (120 CPU) | £864,000 (VCF ask) | £96,000–£120,000 | £744,000–£768,000 | 86% |
| IBM MQ + DB2 (MES integration) | £280,000 | £98,000 | £182,000 | 65% |
| Total | £3,104,000 | £893,000–£917,000 | £2,187,000–£2,211,000 | ~70% |
15-minute consultation. We review your vendor support costs, identify GxP-compatible savings opportunities, and give you a commercial model comparing your current spend to TPS — without any obligation.